Notably, case 2 was designed to fit within the inclusion criteria of the RTOG 9802 trial which showed a significant OS benefit not only for astrocytomas but also for IDH mut gliomas [2]. This evidence concerns the gene IDH1 and astrocytoma (excluding glioblastoma).